Pharmacotherapy for schizophrenia in postmenopausal women

References

• Riecher-Rössler A. Sex and gender differences in mental disorders. Lancet Psychiatry. 2017;4:8–9.
   PubMed Web of Science ®Google Scholar
• Cerosimo MG, Benarroch EE. Estrogen actions in the nervous system. Neurology. 2015;85:263–273.
   PubMed Web of Science ®Google Scholar
• Barth C, Villringer A, Sacher J. Sex hormones affect neurotransmitters and shape the adult female brain during hormonal transition periods. Front Neurosci. 2015;20:37.
   Google Scholar
• Riecher-Rössler A. Oestrogens, prolactin, hypothalamic-pituitary-gonadal axis, and schizophrenic psychoses. Lancet Psychiatry. 2017;4:63–72.
   PubMed Web of Science ®Google Scholar
• Häfner H, Riecher-Rössler A, Maurer K, et al. First onset and early symptomatology of schizophrenia. A chapter of epidemiological and neurobiological research into age and sex differences. Eur Arch Psychiatry Clin Neurosci. 1992;242:109–118.
   PubMed Web of Science ®Google Scholar
• Ochoa S, Usall J, Cobo J, et al. Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review. Schizophr Res Treatment. 2012;2012:916198.
   PubMedGoogle Scholar
• Crawford MB, DeLisi LE. Issues related to sex differences in antipsychotic treatment. Curr Opin Psychiatry. 2016;29:211–227.
   PubMed Web of Science ®Google Scholar
• Messias E, Chen CY, Eaton WW. Epidemiology of schizophrenia: review of findings and myths. Psychiatr Clin North Am. 2007;30:323–338.
   PubMed Web of Science ®Google Scholar
• Searles S, Makarewicz JA, Dumas JA. The role of estradiol in schizophrenia diagnosis and symptoms in postmenopausal women. Schizophr Res. 2017; published online 2017 Jun 3. DOI:10.1016/j.schres.2017.05.024
   PubMed Web of Science ®Google Scholar
• Seeman MV. Gender and the onset of schizophrenia: neurohumoral influences. J Psychiatry Neurosci. 1981;6:136–138.
   Google Scholar
• Riecher-Rössler A, Häfner H, Stumbaum M, et al. Can estradiol modulate schizophrenic symptomatology? Schizophr Bull. 1994;20:203–214.
   PubMed Web of Science ®Google Scholar
• Bergemann N, Parzer P, Runnebaum B, et al. Estrogen, menstrual cycle phases, and psychopathology in women suffering from schizophrenia. Psychol Med. 2007;37:1427–1436.
   PubMed Web of Science ®Google Scholar
• Bergemann N, Parzer P, Nagl I, et al. Acute psychiatric admission and menstrual cycle phase in women with schizophrenia. Arch Womens Ment Health. 2002;5:119–126.
   PubMedGoogle Scholar
• Seeman MV. Treating schizophrenia at the time of menopause. Maturitas. 2012;72:117–120.
   PubMed Web of Science ®Google Scholar
• González-Rodríguez A, Molina-Andreu O, Penadés R, et al. Delusional disorder over the reproductive life span: the potential influence of menopause on the clinical course. Schizophr Res Treatment. 2015;2015:979605.
   PubMedGoogle Scholar
• Arad M, Weiner I. Contrasting effects of increased and decreased dopamine transmission on latent inhibition in ovariectomized rats and their modulation by 17beta-estradiol: an animal model of menopausal psychosis? Neuropsychopharmacology. 2010;35:1570–1582.
   PubMed Web of Science ®Google Scholar
• Arad M, Weiner I. Disruption of latent inhibition induced by ovariectomy can be reversed by estradiol and clozapine as well as by co-administration of haloperidol with estradiol but not by haloperidol alone. Psychopharmacology (Berl). 2009;206:731–740.
   PubMed Web of Science ®Google Scholar
• Howard R, Rabins P, Seeman MV, et al. Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: an international consensus. Am J Psychiatry. 2000;157:172–178.
   PubMed Web of Science ®Google Scholar
• Seeman MV. Interaction of sex, age, and neuroleptic dose. Compr Psychiatry. 1983;24:125–128.
   PubMed Web of Science ®Google Scholar
• Brzezinski A, Brzezinski-Sinai NA, Seeman MV. Treating schizophrenia during menopause. Menopause. 2017;24:582–588.
   PubMed Web of Science ®Google Scholar
• Barbui C, Nose M, Bindman J, et al. Sex differences in the subjective tolerability of antipsychotic drugs. J Clin Psychopharmacol. 2005;25:521–526.
   PubMed Web of Science ®Google Scholar
• González-Rodríguez A, Catalán R, Penadés R, et al. Antipsychotic response worsens with postmenopausal duration in women with schizophrenia. J Clin Psychopharmacol. 2016;36:580–587.
   PubMed Web of Science ®Google Scholar
• González-Rodríguez A, Bernardo M, Penadés R, et al. Do FSH/LH ratio and gonadal hormone levels predict clinical improvement in postmenopausal schizophrenia women? Arch Womens Ment Health. 2017;20:613–620.
   PubMed Web of Science ®Google Scholar
• González-Rodríguez A, Catalán R, Penadés R, et al. The oestrogen dysfunction hypothesis in schizophrenia: the need for an integrative approach to treat postmenopausal women. Aust N Z J Psychiatry. 2016;50:1207–1208.
   PubMed Web of Science ®Google Scholar
• Shi S, Klotz U. Age-related changes in pharmacokinetics. Curr Drug Metabol. 2011;12:601–610.
   PubMed Web of Science ®Google Scholar
• Castberg I, Westin AA, Skogvoll E, et al. Effects of age and gender on the serum levels of clozapine, olanzapine, risperidone, and quetiapine. Acta Psychiatr Scand. 2017;136:455–464.
   PubMed Web of Science ®Google Scholar
• Franconi F, Brunelleschi S, Steardo L, et al. Gender differences in drug responses. Pharmacological Res. 2007;5:81–95.
   Web of Science ®Google Scholar
• Waxman DJ, Holloway MG. Sex differences in the expression of hepatic drug metabolizing enzymes. Mol Pharmacol. 2009;76:215–228.
   PubMed Web of Science ®Google Scholar
• Costantine MM. Physiologic and pharmacokinetic changes in pregnancy. Front Pharmacol. 2014;5:65.
   PubMed Web of Science ®Google Scholar
• Kashuba AD, Nafziger AN. Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs. Clin Pharmacokinet. 1998;34:203–218.
   PubMed Web of Science ®Google Scholar
• Pariente G, Leibson T, Carls A, et al. Pregnancy-associated changes in pharmacokinetics: a systematic review. PLOS Med. 2016; published online 2016 Nov 1. Doi:10.1371/journal.pmed.1002160.
   PubMed Web of Science ®Google Scholar
• Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Therapeut. 2013;138:103–141.
   PubMed Web of Science ®Google Scholar
• Kaasinen V, Nagren K, Hietala J, et al. Sex differences in extrastriatal dopamine d(2)-like receptors in the human brain. Am J Psychiatry. 2001;158:308–311.
   PubMed Web of Science ®Google Scholar
• Seeman MV. Secondary effects of antipsychotics: women at greater risk than Men. Schizophr Bull. 2009;35:937–948.
   PubMed Web of Science ®Google Scholar
• Correll CU, Detraux J, De Lepeleire J, et al. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015;14:119–136.
   PubMed Web of Science ®Google Scholar
• Auro K, Joensuu A, Fischer K, et al. A metabolic view on menopause and ageing. Nat Comm. 2014;5:4708. Article number: 4708.
   PubMed Web of Science ®Google Scholar
• Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metabol. 2003;88:2404–2411.
   PubMed Web of Science ®Google Scholar
• Darpo B, Karnad DR, Badilini F, et al. Are women more susceptible than men to drug-induced QT prolongation? Concentration–qTc modelling in a phase 1 study with oral rac-sotalol. Br J Clin Pharmacol. 2014;77:522–531.
   PubMed Web of Science ®Google Scholar
• Wang MT, Liou JT, Huang YW, et al. Use of antipsychotics and risk of venous thromboembolism in postmenopausal women. A population-based nested case-control study. Thromb Haemost. 2016;115:1209–1219.
   PubMed Web of Science ®Google Scholar
• Kahl KG, Westhoff-Bleck M, Krüger THC. Effects of psychopharmacological treatment with antipsychotic drugs on the vascular system. Vascul Pharmacol. 2017;96–98:11–18. published online 2017 Jan.
   PubMed Web of Science ®Google Scholar
• Meaney AM, O’Keane V. Bone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variables. Schizophr Res. 2007;93:136–143.
   PubMed Web of Science ®Google Scholar
• Bolton JM, Targownik LE, Leung S, et al. Risk of low bone mineral density associated with psychotropic medications and mental disorders in postmenopausal women. J Clin Psychopharmacol. 2011;31:56–60.
   PubMed Web of Science ®Google Scholar
• Lin CH, Lin CY, Huang TL, et al. Sex-specific factors for bone density in patients with schizophrenia. Int Clin Psychopharmacol. 2015;30:96–10233.
   PubMed Web of Science ®Google Scholar
• Liang Y, Huang J, Tian JB, et al. Factors associated with decreased bone mineral density in postmenopausal women with schizophrenia. Clin Interv Aging. 2016;11:153–157.
   PubMed Web of Science ®Google Scholar
• Solmi M, Murru A, Pacchiarotti I, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017;13:757–777.
   PubMed Web of Science ®Google Scholar
• De Hert M, Peuskens J, Sabbe T, et al. Relationship between prolactin, breast cancer risk, and antipsychotics in patients with schizophrenia: a critical review. Acta Psychiatr Scand. 2016;133:5–22.
   PubMed Web of Science ®Google Scholar
• Sandyk R. Biological determinants and risk factors for tardive dyskinesia in schizophrenia. Int J Neurosci. 1993;69:35–51.
   PubMed Web of Science ®Google Scholar
• Turrone P, Seeman MV, Silvestri S. Estrogen receptor activation and tardive dyskinesia. Can J Psychiatry. 2000;45:288–290.
   PubMed Web of Science ®Google Scholar
• Caroff SN, Campbell EC. Drug-induced extrapyramidal syndromes. Psychiatr Clin N Am. 2016;39:391–411.
   PubMed Web of Science ®Google Scholar
• Torniainen M, Mittendorfer-Rutz E, Tanskanen A, et al. Antipsychotic treatment and mortality in schizophrenia. Schizophr Bull. 2015;41:656–663.
   PubMed Web of Science ®Google Scholar
• Kulkarni J, De Castella A, Smith D, et al. A clinical trial of the effects of estrogen in acutely psychotic women. Schizophr Res. 1996;20:247–252.
   PubMed Web of Science ®Google Scholar
• Kulkarni J, Riedel A, De Castella AR, et al. Estrogen - a potential treatment for schizophrenia. Schizophr Res. 2001;48:137–144.
   PubMed Web of Science ®Google Scholar
• Kulkarni J, De Castella A, Fitzgerald PB, et al. Estrogen in severe mental illness: a potential new treatment approach. Arch Gen Psychiatry. 2008;65:955–960.
   PubMed Web of Science ®Google Scholar
• Kulkarni J, Riedel A, De Castella AR, et al. A clinical trial of adjunctive oestrogen treatment in women with schizophrenia. Arch Womens Ment Health. 2002;5:99–104.
   PubMedGoogle Scholar
• Akhondzadeh S, Nejatisafa AA, Amini H, et al. Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:1007–1012.
   PubMed Web of Science ®Google Scholar
• Santen RJ, Kagan R, Altomare CJ, et al. Current and evolving approaches to individualizing estrogen receptor-based therapy for menopausal women. J Clin Endocrinol Metab. 2014;99:733–747.
   PubMed Web of Science ®Google Scholar
• Hickey M, McNamara HC, Mishra GD. Menopausal estrogen therapy and breast cancer mortality. Jama. 2018;319:193.
   PubMed Web of Science ®Google Scholar
• Arnson Y, Rozanski A, Gransar H, et al. Hormone replacement therapy is associated with less coronary atherosclerosis and lower mortality. J Am Coll Cardiol. 2017;69. Supplement. DOI:10.1016/S0735-1097(17)34797-6.
   Web of Science ®Google Scholar
• McGregor C, Riordan A, Thornton J. Estrogens and the cognitive symptoms of schizophrenia: possible neuroprotective mechanisms. Front Neuroendocrinol. 2017;47:19–33.
   PubMed Web of Science ®Google Scholar
• Pinkerton JAV, Aguirre SF, Blake J, et al. The 2017 hormone therapy position statement of The North American Menopause Society. Accessed April 16, 2018. Available from: https://uic.pure.elsevier.com/en/publications/the-2017-hormone-therapy-position-statement-of-the-north-american
   Google Scholar
• Schroeder A, Hudson M, Du X, et al. Estradiol and raloxifene modulate hippocampal gamma oscillations during a spatial memory task. Psychoneuroendocrinol. 2017;78:85–92.
   PubMed Web of Science ®Google Scholar
• Gogos A, Van Den Buuse M. Comparing the effects of 17β-oestradiol and the selective oestrogen receptor modulators, raloxifene and tamoxifen, on prepulse inhibition in female rats. Schizophr Res. 2015;168:634–639.
   PubMed Web of Science ®Google Scholar
• De Boer J, Prikken M, Lei WU, et al. The effect of raloxifene augmentation in men and women with a schizophrenia spectrum disorder: a systematic review and meta-analysis. NPJ Schizophr. 2018; published online 2018 Jan 10. DOI:10.1038/s41537-017-0043-3
   PubMed Web of Science ®Google Scholar
• Wang Q, Dong X, Wang Y, et al. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a meta-analysis of randomized controlled trials. Arch Womens Ment Health. 2017; DOI:10.1007/s00737-017-0773-2
   Web of Science ®Google Scholar
• Wang Z, Yang Y, Zheng X, et al. Synthesis and biological evaluation of novel cyclopropyl derivatives as subtype-selective ligands for estrogen receptor. J Pharm Pharmacol. 2018; published online 2018 Mar 27. DOI:10.1111/jphp.12908
   Web of Science ®Google Scholar
• Pickar JH, Boucher M, Morgenstern D, Tissue selective estrogen complex (TSEC): a review. Menopause. 2018:1. published online 2018 Mar 12. Doi:10.1097/GME.0000000000001095
   Web of Science ®Google Scholar
• Bratek A, Krysta K, Drzyzga K, et al. The role of selective estrogen receptor modulators in the treatment of schizophrenia. Psychiatr Danub. 2016;28(Suppl–1):45–48.
   PubMed Web of Science ®Google Scholar
• Tharoor H, Goyal A. Raloxifene trial in postmenopausal woman with treatment-resistant schizophrenia. Arch Womens Ment Health. 2015;18:741–742.
   PubMed Web of Science ®Google Scholar
• Kulkarni J, Gavrilidis E, Gwini SM, et al. Effect of adjunctive raloxifene therapy on severity of refractory schizophrenia in women: a randomized clinical trial. JAMA Psychiatry. 2016;73:947–954.
   PubMed Web of Science ®Google Scholar
• Dhandapani A, Narayanaswamy JC, Venkatasubramanian G. Adjuvant raloxifene treatment for negative symptoms of schizophrenia. Asian J Psychiatr. 2013;6:254–255.
   PubMedGoogle Scholar
• Raveendranathan D, Shivakumar V, Jayaram N, et al. Beneficial effects of add-on raloxifene in schizophrenia. Arch Womens Ment Health. 2012;15:147–148.
   PubMed Web of Science ®Google Scholar
• Shivakumar V, Venkatasubramanian G. Successful use of adjuvant raloxifene treatment in clozapine-resistant schizophrenia. Indian J Psychiatry. 2012;54:394.
   PubMedGoogle Scholar
• Kulkarni J, Gurvich C, Lee SJ, et al. Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia. Psychoneuroendocrinol. 2010;35:1142–1147.
   PubMed Web of Science ®Google Scholar
• Usall J, Huerta-Ramos E, Iniesta R, et al. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry. 2011;72:1552–1557.
   PubMed Web of Science ®Google Scholar
• Kianimehr G, Fatehi F, Hashempoor S, et al. Raloxifene adjunctive therapy for postmenopausal women suffering from chronic schizophrenia: a randomized double-blind and placebo controlled trial. Daru. 2014;22:55.
   PubMed Web of Science ®Google Scholar
• Usall J, Huerta-Ramos E, Labad J, et al. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a 24-week double-blind, randomized, parallel, placebo-controlled trial. Schizophr Bull. 2016;42:309–317.
   PubMed Web of Science ®Google Scholar
• Weiser M, Levi L, Burshtein S, et al. Raloxifene plus antipsychotics versus placebo plus antipsychotics in severely ill decompensated postmenopausal women with schizophrenia or schizoaffective disorder: A randomized controlled trial. J Clin Psychiatry. 2017;78:e758–e65.
   PubMed Web of Science ®Google Scholar
• Ji E, Weickert CS, Lenroot R, et al. Adjunctive selective estrogen receptor modulator increases neural activity in the hippocampus and inferior frontal gyrus during emotional face recognition in schizophrenia. Transl Psychiatry. 2016;6:e795.
   PubMed Web of Science ®Google Scholar
• Weickert TW, Weickert CS. Raloxifene improves cognition in schizophrenia: spurious result or valid effect? Front Psychiatry. 2017;8:202.
   PubMed Web of Science ®Google Scholar
• Kindler J, Weickert CS, Skilleter AJ, et al. Selective estrogen receptor modulation increases hippocampal activity during probabilistic association learning in schizophrenia. Neuropsychopharmacol. 2015;40:2388–2397.
   PubMed Web of Science ®Google Scholar
• Weickert TW, Allen KM, Weickert CS. Potential role of oestrogen modulation in the treatment of neurocognitive deficits in schizophrenia. CNS Drugs. 2016;30:125–133.
   PubMed Web of Science ®Google Scholar
• Weickert TW, Weinberg D, Lenroot R, et al. Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia. Mol Psychiatry. 2015;20:685–694.
   PubMed Web of Science ®Google Scholar
• Huerta-Ramos E, Iniesta R, Ochoa S, et al. Effects of raloxifene on cognition in postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. Eur Neuropsychopharmacol. 2014;24:223–231.
   PubMed Web of Science ®Google Scholar
• Labad J, Martorell L, Huerta-Ramos E, et al. Pharmacogenetic study of the effects of raloxifene on negative symptoms of postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. Eur Neuropsychopharmacol. 2016;26:1683–1689.
   PubMed Web of Science ®Google Scholar
• Provinciali N, Suen C, Dunn BK, et al. Raloxifene hydrochloride for breast cancer risk reduction in postmenopausal women. Expert Rev Clin Pharmacol. 2016; published online 2016 Sept 12. DOI:10.1080/17512433.2016.1231575
   PubMed Web of Science ®Google Scholar
• Ellis AJ, Hendrick VM, Williams R, et al. Selective estrogen receptor modulators in clinical practice: a safety overview. Expert Opin Drug Saf. 2015;14:921–934.
   PubMed Web of Science ®Google Scholar
• Franco OH, Chowdhury R, Troup J, et al. Use of plant-based therapies and menopausal symptoms. a systematic review and meta-analysis. Jama. 2016;315:2554–2563.
   PubMed Web of Science ®Google Scholar
• Hernandez G, Zhao L, Franke AA, et al. Pharmacokinetics and safety profile of single-dose administration of an estrogen receptor β-selective phytoestrogenic (phytoSERM) formulation in perimenopausal and postmenopausal women. Menopause. 2018;25:191–196.
   PubMed Web of Science ®Google Scholar
• Lecomte S, Lelong M, Bourgine G, et al. Assessment of the potential activity of major dietary compounds as selective estrogen receptor modulators in two distinct cell models for proliferation and differentiation. Toxicol Appl Pharmacol. 2017;325:61–70.
   PubMed Web of Science ®Google Scholar
• Rietjens IMCM, Louisse J, Beekman K. The potential health effects of dietary phytoestrogens. Br J Pharmacol. 2017;174:1263–1280.
   PubMed Web of Science ®Google Scholar
• Takase M, Kanahara N, Oda Y, et al. Dopamine supersensitivity psychosis and dopamine partial agonist: a retrospective survey of failure of switching to aripiprazole in schizophrenia. J Psychopharmacol. 2015;29:383–389.
   PubMed Web of Science ®Google Scholar
• Pringsheim U, Kelly M, Urness D, et al. Physical health and drug safety in individuals with schizophrenia. Can J Psychiatry. 2017;62:673–683.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341–1352.
   PubMed Web of Science ®Google Scholar
• Lertxundi U, Hernandez R, Albeniz JM, et al. Possible interaction between letrozole and long-acting injectable zuclopenthixol. Nord J Psychiatry. 2015;69:79–80.
   PubMed Web of Science ®Google Scholar
• Papaleo F, Sannino S, Piras F, et al. Sex-dichotomous effects of functional COMT genetic variations on cognitive functions disappear after menopause in both health and schizophrenia. Eur Neuropsychopharmacol. 2015;25:2349–2363.
   PubMed Web of Science ®Google Scholar
• Fukuta H, Ito I, Tateno A, et al. Effects of menopause on brain structural changes in schizophrenia. Psychiatry Clin Neurosci. 2013;67:3–11.
   PubMed Web of Science ®Google Scholar
• McCammon JM, Sive H. Challenges in understanding psychiatric disorders and developing therapeutics: a role for zebrafish. Dis Model Mech. 2015;8:647–656.
   PubMed Web of Science ®Google Scholar
• Tye KM, Deisseroth K. Optogenetic invstigation of neural circuits underlying brain disease in animal models. Nat Rev Neurosci. 2012;13:251–265.
   PubMed Web of Science ®Google Scholar
• Kosinski M, Behrend T. Big data in the behavioral sciences. Curr Opin Behav Sci. 2017;18:4–6.
   Google Scholar